Last reviewed · How we verify
sIPV batch 3
sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.
sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3. Used for Prevention of poliomyelitis (polio) in infants and children.
At a glance
| Generic name | sIPV batch 3 |
|---|---|
| Sponsor | Institute of Medical Biology, Chinese Academy of Medical Sciences |
| Drug class | Inactivated viral vaccine |
| Target | Poliovirus types 1, 2, and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
sIPV (Sabin inactivated poliovirus vaccine) is prepared from attenuated poliovirus strains that are chemically inactivated, making them unable to cause disease while retaining immunogenicity. When administered, it triggers both humoral (antibody) and cellular immune responses that provide protection against wild-type poliovirus infection. This vaccine is used as part of routine immunization programs to prevent poliomyelitis.
Approved indications
- Prevention of poliomyelitis (polio) in infants and children
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sIPV batch 3 CI brief — competitive landscape report
- sIPV batch 3 updates RSS · CI watch RSS
- Institute of Medical Biology, Chinese Academy of Medical Sciences portfolio CI